LILRB4: A Potential Drug Target and Biomarker (G11006)

Target Name: LILRB4

NCBI ID: G11006

LILRB4

LILRB4: A Potential Drug Target and Biomarker

LILRB4 (long interleukin-4 receptor B4) is a protein that is expressed in various tissues throughout the body. It is a member of the interleukin-4 receptor family, which is a protein that is involved in the regulation of immune and inflammatory responses. LILRB4 is also known as LIR5, and it is a potential drug target and biomarker.

The interleukin-4 receptor family plays a crucial role in the regulation of immune responses. It is involved in the development and maintenance of T cells, which are a critical part of the immune system. T cells are responsible for recognizing and responding to foreign substances in the body, and they are essential for fighting off infections and diseases.

LILRB4 is a protein that is expressed in various tissues throughout the body, including the skin, the lungs, and the gastrointestinal tract. It is a member of the interleukin-4 receptor family, and it is involved in the regulation of immune responses.

One of the key functions of LILRB4 is its role in the regulation of T cell development. T cells are a critical part of the immune system, and they are responsible for recognizing and responding to foreign substances in the body. LILRB4 is involved in the development and maintenance of T cells, and it is essential for the proper functioning of the immune system.

In addition to its role in T cell development, LILRB4 is also involved in the regulation of inflammation. Inflammation is a natural response of the immune system, but it can also be a source of pain and damage. LILRB4 is involved in the regulation of inflammation, and it is essential for the proper functioning of the immune system.

LILRB4 is also a potential drug target. Its involvement in the regulation of immune and inflammatory responses makes it an attractive target for researchers to study. By targeting LILRB4, researchers may be able to develop new treatments for a variety of diseases.

In addition to its potential as a drug target, LILRB4 is also a potential biomarker. Its involvement in the regulation of immune and inflammatory responses makes it an attractive target for researchers to study. By studying the effects of LILRB4 on T cells and the immune system, researchers may be able to develop new insights into the underlying mechanisms of various diseases.

Overall, LILRB4 is a protein that is involved in the regulation of immune and inflammatory responses. As a potential drug target and biomarker, LILRB4 is a promising target for researchers to study. By studying its effects on T cells and the immune system, researchers may be able to develop new treatments for a variety of diseases.

Protein Name: Leukocyte Immunoglobulin Like Receptor B4

Functions: Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance (PubMed:11875462). Receptor for FN1 (PubMed:34089617). Receptor for apolipoprotein APOE (PubMed:30333625). Receptor for ALCAM/CD166 (PubMed:29263213). Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:9151699). Inhibits FCGR1A/CD64-mediated monocyte activation by inducing phosphatase-mediated down-regulation of the phosphorylation of multiple proteins including LCK, SYK, LAT and ERK, leading to a reduction in TNF production (PubMed:19833736). This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:34089617). Inhibits T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytoxic T cells and enhancing the generation of CD8+ T suppressor cells (PubMed:16493035, PubMed:19833736, PubMed:29263213). Induces up-regulation of CD86 on dendritic cells (PubMed:19860908). Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation (PubMed:11875462)

The "LILRB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets